2961 related articles for article (PubMed ID: 16691383)
1. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
Hassa H; Tanir HM; Yildiz Z
Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
[TBL] [Abstract][Full Text] [Related]
2. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population.
Pehlivanov B; Orbetzova M
Gynecol Endocrinol; 2007 Oct; 23(10):604-9. PubMed ID: 17852429
[TBL] [Abstract][Full Text] [Related]
4. Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters.
Carmina E; Orio F; Palomba S; Longo RA; Lombardi G; Lobo RA
Fertil Steril; 2005 Aug; 84(2):413-9. PubMed ID: 16084883
[TBL] [Abstract][Full Text] [Related]
5. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
6. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
7. Endocrinological markers for assessing hyperandrogenemia in women classified as having polycystic ovary syndrome (PCOS) according to the revised 2003 diagnostic criteria.
Mueller A; Dittrich R; Binder H; Hoffmann I; Beckmann MW; Cupisti S
Eur J Med Res; 2006 Dec; 11(12):540-4. PubMed ID: 17182367
[TBL] [Abstract][Full Text] [Related]
8. Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria.
Yilmaz M; Isaoglu U; Delibas IB; Kadanali S
J Obstet Gynaecol Res; 2011 Aug; 37(8):1020-6. PubMed ID: 21481088
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups.
Chang WY; Knochenhauer ES; Bartolucci AA; Azziz R
Fertil Steril; 2005 Jun; 83(6):1717-23. PubMed ID: 15950641
[TBL] [Abstract][Full Text] [Related]
10. [Clinical, hormonal and metabolic characteristics of different phenotypes of polycystic ovary syndrome, in Bulgarian population].
Kavardzhikova S; Pechlivanov B
Akush Ginekol (Sofiia); 2010; 49(4):32-7. PubMed ID: 20734639
[TBL] [Abstract][Full Text] [Related]
11. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
12. Clinical and metabolic characteristics of polycystic ovary syndrome without polycystic ovary: a pilot study on Chinese women.
Shi Y; Gao X; Sun X; Zhang P; Chen Z
Fertil Steril; 2008 Oct; 90(4):1139-43. PubMed ID: 17889857
[TBL] [Abstract][Full Text] [Related]
13. Ovarian morphology and prevalence of polycystic ovary syndrome in reproductive aged women with or without mild acne.
Kelekci KH; Kelekci S; Incki K; Ozdemir O; Yilmaz B
Int J Dermatol; 2010 Jul; 49(7):775-9. PubMed ID: 20618496
[TBL] [Abstract][Full Text] [Related]
14. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
15. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women.
Chae SJ; Kim JJ; Choi YM; Hwang KR; Jee BC; Ku SY; Suh CS; Kim SH; Kim JG; Moon SY
Hum Reprod; 2008 Aug; 23(8):1924-31. PubMed ID: 18579512
[TBL] [Abstract][Full Text] [Related]
16. Is prostate-specific antigen a potential new marker of androgen excess in polycystic ovary syndrome?
Vural B; Ozkan S; Bodur H
J Obstet Gynaecol Res; 2007 Apr; 33(2):166-73. PubMed ID: 17441890
[TBL] [Abstract][Full Text] [Related]
17. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.
Diamanti-Kandarakis E; Kouli CR; Bergiele AT; Filandra FA; Tsianateli TC; Spina GG; Zapanti ED; Bartzis MI
J Clin Endocrinol Metab; 1999 Nov; 84(11):4006-11. PubMed ID: 10566641
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of 3alpha-androstanediol glucuronide in young women with polycystic ovary syndrome, idiopathic hirsutism and in normal subjects.
Meczekalski B; Slopien R; Warenik-Szymankiewicz A
Eur J Obstet Gynecol Reprod Biol; 2007 May; 132(1):88-92. PubMed ID: 16979812
[TBL] [Abstract][Full Text] [Related]
19. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype.
Legro RS; Chiu P; Kunselman AR; Bentley CM; Dodson WC; Dunaif A
J Clin Endocrinol Metab; 2005 May; 90(5):2571-9. PubMed ID: 15713728
[TBL] [Abstract][Full Text] [Related]
20. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]